,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-04-15 08:00:00,The following are the top rated Healthcare stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett .,0.043228548020124435,0.004656202159821987,0.9521152973175049,neutral,0.038572344928979874
1,2018-04-15 08:00:00,"This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.",0.20986133813858032,0.006538537796586752,0.7836001515388489,neutral,0.20332279801368713
2,2018-04-15 08:00:00,BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry.,0.6385758519172668,0.010137596167623997,0.35128650069236755,positive,0.6284382343292236
3,2018-04-15 08:00:00,The rating according to our strategy based on Warren Buffett is 93% based on the firm's underlying fundamentals and the stock's valuation.,0.032949190586805344,0.005188412964344025,0.9618624448776245,neutral,0.02776077762246132
4,2018-04-15 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2018-04-15 08:00:00,Company Description: Biogen Inc. is a biopharmaceutical company.,0.015894627198576927,0.0073434701189398766,0.9767618775367737,neutral,0.00855115707963705
6,2018-04-15 08:00:00,"The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.",0.06928692013025284,0.00443440955132246,0.9262787103652954,neutral,0.0648525133728981
7,2018-04-15 08:00:00,"The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis ( MS ), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).",0.05885586515069008,0.004554904066026211,0.9365891814231873,neutral,0.05430096015334129
8,2018-04-15 08:00:00,"It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies.",0.4847475290298462,0.009223067201673985,0.5060294270515442,neutral,0.4755244553089142
9,2018-04-15 08:00:00,"The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.",0.05369625240564346,0.005773114040493965,0.9405306577682495,neutral,0.04792314022779465
10,2018-04-15 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
11,2018-04-15 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
12,2018-04-15 08:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INTUITIVE SURGICAL, INC. ( ISRG ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.637584924697876,0.010514910332858562,0.3519001305103302,positive,0.6270700097084045
13,2018-04-15 08:00:00,The rating according to our strategy based on Warren Buffett is 79% based on the firm's underlying fundamentals and the stock's valuation.,0.028929824009537697,0.005225156433880329,0.965844988822937,neutral,0.023704666644334793
14,2018-04-15 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
15,2018-04-15 08:00:00,"Company Description: Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories.",0.02185518853366375,0.006197228562086821,0.9719475507736206,neutral,0.015657959505915642
16,2018-04-15 08:00:00,"The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system.",0.020238682627677917,0.007399392314255238,0.9723619222640991,neutral,0.01283929031342268
17,2018-04-15 08:00:00,"The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports.",0.02189486473798752,0.010379241779446602,0.9677258729934692,neutral,0.011515622958540916
18,2018-04-15 08:00:00,"The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition ( HD ) vision.",0.14674335718154907,0.005833636038005352,0.8474230170249939,neutral,0.14090971648693085
19,2018-04-15 08:00:00,"Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System.",0.08619140088558197,0.005270529538393021,0.9085380434989929,neutral,0.08092087507247925
20,2018-04-15 08:00:00,The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.,0.01875384896993637,0.00609822990372777,0.9751479625701904,neutral,0.012655619531869888
21,2018-04-15 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
22,2018-04-15 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
23,2018-04-15 08:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

HENRY SCHEIN, INC. ( HSIC ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.4482971429824829,0.008918996900320053,0.5427838563919067,neutral,0.43937814235687256
24,2018-04-15 08:00:00,The rating according to our strategy based on Warren Buffett is 72% based on the firm's underlying fundamentals and the stock's valuation.,0.030370399355888367,0.005157763138413429,0.9644718766212463,neutral,0.025212636217474937
25,2018-04-15 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
26,2018-04-15 08:00:00,"Company Description: Henry Schein, Inc. is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners.",0.03628134727478027,0.0052106487564742565,0.9585080146789551,neutral,0.03107069805264473
27,2018-04-15 08:00:00,"The Company operates through two segments: healthcare distribution, and technology and value-added services.",0.016387267038226128,0.00638753455132246,0.9772252440452576,neutral,0.009999732486903667
28,2018-04-15 08:00:00,"The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.",0.015017230994999409,0.007259625010192394,0.9777231216430664,neutral,0.0077576059848070145
29,2018-04-15 08:00:00,"The technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners.",0.02448747307062149,0.005064907018095255,0.9704475998878479,neutral,0.019422566518187523
30,2018-04-15 08:00:00,Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics.,0.020227594301104546,0.005537560675293207,0.9742348194122314,neutral,0.014690034091472626
31,2018-04-15 08:00:00,"The Company provides its services to dental practitioners and laboratories, animal health clinics and physician practices, as well as government and institutional healthcare clinics.",0.025317931547760963,0.004989595152437687,0.9696924686431885,neutral,0.020328335464000702
32,2018-04-15 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
33,2018-04-15 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
34,2018-04-15 08:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

MCKESSON CORPORATION (MCK) is a large-cap value stock in the Biotechnology & Drugs industry.",0.056917641311883926,0.00545114278793335,0.9376312494277954,neutral,0.05146649852395058
35,2018-04-15 08:00:00,The rating according to our strategy based on Warren Buffett is 72% based on the firm's underlying fundamentals and the stock's valuation.,0.030370399355888367,0.005157763138413429,0.9644718766212463,neutral,0.025212636217474937
36,2018-04-15 08:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
37,2018-04-15 08:00:00,"Company Description: McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company.",0.023271040990948677,0.005979144014418125,0.9707497954368591,neutral,0.017291896045207977
38,2018-04-15 08:00:00,"The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.",0.4587045907974243,0.00819134060293436,0.5331040620803833,neutral,0.45051324367523193
39,2018-04-15 08:00:00,It operates through two segments: McKesson Distribution Solutions and McKesson Technology Solutions.,0.015340907499194145,0.008406206965446472,0.9762528538703918,neutral,0.006934700533747673
40,2018-04-15 08:00:00,"The distribution solutions segment distributes branded and generic pharmaceutical drugs and other healthcare-related products internationally and provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices.",0.0563650019466877,0.00508128572255373,0.9385536909103394,neutral,0.05128371715545654
41,2018-04-15 08:00:00,"Technology Solutions segment provides software and analytics, network solutions and technology-enabled services.",0.021161876618862152,0.005682352464646101,0.9731557965278625,neutral,0.015479523688554764
42,2018-04-15 08:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
43,2018-04-15 08:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
44,2018-04-15 08:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Warren Buffett has returned 197.50% vs. 150.24% for the S&P 500.",0.48890435695648193,0.4697594940662384,0.041336119174957275,positive,0.01914486289024353
45,2018-04-15 08:00:00,"For more details on this strategy, click here

About Warren Buffett : Warren Buffett is considered by many to be the greatest investor of all time.",0.1991606056690216,0.011050635948777199,0.7897887825965881,neutral,0.18810996413230896
46,2018-04-15 08:00:00,"As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men.",0.7431123852729797,0.038232944905757904,0.21865463256835938,positive,0.7048794627189636
47,2018-04-15 08:00:00,(Forbes puts his net worth at $37 billion.),0.021339498460292816,0.011338518932461739,0.967322051525116,neutral,0.010000979527831078
48,2018-04-15 08:00:00,"Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards.",0.03567022085189819,0.03917572647333145,0.9251540899276733,neutral,-0.003505505621433258
49,2018-04-15 08:00:00,"His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.",0.10358904302120209,0.011022992432117462,0.8853879570960999,neutral,0.09256605058908463
50,2018-04-15 08:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
51,2018-04-15 08:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751807361841202,0.01020655408501625,0.9022754430770874,neutral,0.07731151580810547
52,2018-04-15 08:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221812710165977,0.018771812319755554,0.9720063209533691,neutral,-0.009549999609589577
